Drug intelligence / Profile preview

ampicillin + sulbactam

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Oral
01

Overview

Ampicillin + sulbactam is a fixed-dose combination antibiotic consisting of the semisynthetic penicillin derivative ampicillin and the beta-lactamase inhibitor sulbactam. Ampicillin acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death in susceptible bacteria. Sulbactam has minimal antibacterial activity on its own but irreversibly inhibits many beta-lactamases produced by resistant bacteria, thereby protecting ampicillin from enzymatic degradation. This combination extends the spectrum of activity of ampicillin to include organisms that produce beta-lactamase enzymes. It is primarily indicated for the treatment of infections such as skin and skin structure infections, intra-abdominal infections, gynecological infections, urinary tract infections, pneumonia, pelvic inflammatory disease, orbital cellulitis, and other susceptible bacterial infections[1][2][3][4][5][6][7][8][9][10].

Brand names
UnasynUnasyn ADD-Vantage
Other names
ampicillin and sulbactamampicillin/sulbactam
02

Targets

Class A BL (Class A beta-lactamase)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ampicillin + sulbactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin + sulbactam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call